角膜交联术（CXL）
眼科项目
≈ ¥8000-15000
(≈ $1100-2100)
大约30-60分钟（含术前准备与术后观察）
免责声明：本站为医疗服务机构，页面信息部分由AI协助制作。健康相关信息不构成医疗建议。如有任何疑问，请咨询医疗专业人士。详情见免责声明
项目介绍
角膜交联术（CXL）在一般公立医院参考费用约¥5600-12000，三甲医院参考费用约¥8000-15000，常用于相关诊断评估与就医安排，费用随医院及地区有所差异。
主要用途
Primary clinical use is halting the progression of progressive keratoconus and other corneal ectasias (e.g., post-LASIK ectasia, pellucid marginal degeneration). It is indicated in patients with documented topographic and/or refractive progression, age ≥12 years, minimum corneal thickness ≥400 µm (epi-off) or ≥320 µm (epi-on/accelerated protocols), and adequate endothelial cell count. Also used off-label for infectious keratitis adjunctive therapy and selected cases of corneal ulcers resistant to conventional treatment.
正常值范围
Corneal Cross-Linking (CXL) is a therapeutic surgical procedure, not a diagnostic laboratory test; therefore, it has no numerical 'normal range' or quantitative biomarker values. Clinical success is assessed qualitatively and quantitatively via postoperative parameters such as corneal topography (e.g., maximum keratometry Kmax < 55 D, change ≤ 1.0 D/year), corneal thickness (>400 µm preoperatively for standard epithelium-off CXL), endothelial cell density (>2000 cells/mm²), and absence of ectasia progression over ≥2 years.
偏低可能原因
N/A — CXL is not a measurable lab value; however, suboptimal clinical outcomes ('low efficacy') may result from: 1) Preoperative corneal thickness <400 µm limiting riboflavin diffusion and UV absorption, 2) Inadequate UV-A irradiance (e.g., <3 mW/cm²) or duration (<30 min), 3) Epithelial non-removal or incomplete debridement in epithelium-off protocols, 4) Riboflavin solution degradation or insufficient stromal saturation, 5) Patient noncompliance with postoperative topical antibiotics/steroids leading to infection or haze.
偏高可能原因
N/A — CXL is not a quantifiable test with high/low values; however, excessive or adverse effects ('high risk outcomes') may arise from: 1) UV-A overdose (irradiance >9 mW/cm² or exposure >30 min) causing endothelial damage or keratocyte apoptosis, 2) Excessive riboflavin concentration leading to oxidative stress beyond therapeutic window, 3) Preexisting severe corneal scarring or thinning (<300 µm) increasing perforation risk, 4) Concomitant use of photosensitizing medications enhancing UV toxicity, 5) Uncontrolled ocular surface disease (e.g., severe dry eye, active herpes keratitis) exacerbating postoperative inflammation.